Skip to main content
. Author manuscript; available in PMC: 2013 Sep 1.
Published in final edited form as: Arthritis Rheum. 2012 Sep;64(9):2937–2946. doi: 10.1002/art.34502

Fig. 1.

Fig. 1

Effect of NAC and placebo on disease activity, as measured by SLEDAI (panel A), BILAG (panel B), and FAS scores (panel C), in 36 SLE patients exposed to placebo (n=9), 1.2 g/day NAC (NAC Dose1, n=9), 2.4 g/day NAC (NAC Dose 2, n=9), 4.8 g/day NAC (NAC Dose 3, n=9), or all doses of NAC considered together (n=27). Data represent mean ± SEM. p values reflect comparison of pretreatment values (visit 1) to values after treatment for 1 month (visit 2), 2 months (visit 3), 3 months (visit 4), or 4 months (visit 5, 3 months of treatment followed by 1 month washout) using two-tailed paired t-test.

HHS Vulnerability Disclosure